Black seed oil nudges down an inflammation marker, mainly in people with obesity

Black seed, Nigella sativa, has a long history as a traditional remedy and is now sold widely as a seed and seed oil supplement. One of its most repeated claims is that it fights inflammation, and C-reactive protein, or CRP, is the standard blood marker used to gauge inflammatory load. The trial evidence on whether the supplement actually moves this marker has been openly described as equivocal, with individual studies pointing in different directions. Pooling those trials is the obvious way to find out whether a real signal sits underneath the noise.

The reviewers searched PubMed, Scopus, ISI Web of Science, the Cochrane library and Google Scholar up to April 2019 for randomised controlled trials testing Nigella sativa seed or seed oil supplementation and reporting CRP. Only five articles contained usable data and entered the analysis. The team pooled weighted mean differences using a random-effects model and ran standard checks for sensitivity and publication bias. They also split the results by participants' baseline body mass index to see whether the effect depended on body size.

Pooled together, the trials showed a significant reduction in serum CRP of 0.55 mg/L, a modest shift. The individual studies disagreed with each other substantially, however. When the reviewers stratified by baseline BMI, that disagreement largely disappeared and a telling pattern emerged: the CRP reduction was only significant in studies of participants with a BMI of 30 or above, where it came out at 0.50 mg/L. In other words, the overall average appears to be carried by the trials in people with obesity.

Before this pooling, the Nigella sativa literature gave no clear answer, and this analysis tidies it into a coherent picture: a small anti-inflammatory signal concentrated in people carrying substantial excess weight. Five trials is a thin base, though, and the authors themselves call for trials with larger samples and longer follow-up before treating the result as confirmed. Whether the effect holds in leaner people, what dose matters, and whether a drop of this size translates into any health outcome all remain open questions.

If you have seen black seed oil marketed as an anti-inflammatory, this is the honest size of the evidence: a statistically significant but small drop in one blood marker, visible mainly in people with a BMI of 30 or above. For leaner readers, the pooled data give no clear signal at all. It is a reason to treat bold anti-inflammatory claims for this supplement with some scepticism, and to remember that a marker shifting slightly is not the same as a disease risk changing.